2026-05-08
Type 2 diabetes: what the “hidden switches” inside our cells are finally revealing
Endocrinology and Metabolism
By Elodie Vaz | Published on May 8,
2026 | 4 min read
Type 2 diabetes is characterized by chronically elevated blood glucose levels resulting from an imbalance between two essential pancreatic hormones: insulin, secreted by beta cells, and glucagon, produced by alpha cells. When insulin production or action declines, or when glucagon production becomes excessive, glucose homeostasis is disrupted. While the genetic foundations of the disease are well documented, the mechanisms regulating gene expression in these cells remain only partially understood. The epigenome—a collection of chemical modifications to DNA that influence gene activity without altering its sequence—is now emerging as a central regulator of these processes.
To gain a better understanding, a team from Lund University set out to establish the most detailed epigenomic map to date of the cells involved in blood glucose regulation. Their objective was to understand how epigenetic profiles control gene expression in beta and alpha cells, and to determine how these profiles are altered in type 2 diabetes.
The researchers analyzed hundreds of thousands of pancreatic cells obtained from 24 individuals, both diabetic and non-diabetic. This large-scale approach made it possible to identify epigenetic signatures specific to each cell type. The study, published on April 24 in Nature Metabolism, focused particularly on DNA methylation, a key mechanism in transcriptional regulation.
To test the functional role of these modifications, the scientists manipulated methylation near the genes encoding insulin and glucagon in cultured beta cells, thereby assessing its direct impact on hormone expression.
The findings show that many genes essential to hormone production are regulated by variations in methylation. “This study made it possible, for the first time, to describe in detail epigenetic profiles specific to each cell type. It shows that many genes essential for insulin and glucagon production are regulated by differences in DNA methylation,” explained lead author Charlotte Ling in a press release.
The researchers also identified marked alterations in diabetic patients. Among them, the epigenetic overexpression of the transcription factor ONECUT2 in beta cells appeared particularly significant. This abnormality disrupts cellular energy production and insulin secretion, potentially contributing to disease progression.
“Here, for the first time, we precisely show which regions regulate insulin and glucagon production through DNA methylation, giving us the opportunity to develop future epigenetics-based treatments,” emphasized Charlotte Ling. “This allows us to better understand why beta cells lose their function in diabetes. In the longer term, this knowledge could help us identify new personalized therapeutic targets,” she added.
This mapping represents a major advance in understanding the molecular mechanisms underlying type 2 diabetes. It highlights the dynamic role of the epigenome in both the function of pancreatic endocrine cells and their pathological alterations.
“We are now trying to understand which of these modifications are reversible and whether this could help beta cells recover their function in people with diabetes. A key issue is determining whether the effects of modifying DNA methylation persist in the cell over time,” explained Charlotte Ling.
Ultimately, this research opens the door to targeted therapeutic strategies capable of specifically modulating the epigenome. Such an approach could transform diabetes management by moving toward precision medicine based on cellular reprogramming.
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans.
Type 2 diabetes is characterized by chronically elevated blood glucose levels resulting from an imbalance between two essential pancreatic hormones: insulin, secreted by beta cells, and glucagon, produced by alpha cells. When insulin production or action declines, or when glucagon production becomes excessive, glucose homeostasis is disrupted. While the genetic foundations of the disease are well documented, the mechanisms regulating gene expression in these cells remain only partially understood. The epigenome—a collection of chemical modifications to DNA that influence gene activity without altering its sequence—is now emerging as a central regulator of these processes.
To gain a better understanding, a team from Lund University set out to establish the most detailed epigenomic map to date of the cells involved in blood glucose regulation. Their objective was to understand how epigenetic profiles control gene expression in beta and alpha cells, and to determine how these profiles are altered in type 2 diabetes.
Behind the scenes of the cells controlling blood sugar
The researchers analyzed hundreds of thousands of pancreatic cells obtained from 24 individuals, both diabetic and non-diabetic. This large-scale approach made it possible to identify epigenetic signatures specific to each cell type. The study, published on April 24 in Nature Metabolism, focused particularly on DNA methylation, a key mechanism in transcriptional regulation.
To test the functional role of these modifications, the scientists manipulated methylation near the genes encoding insulin and glucagon in cultured beta cells, thereby assessing its direct impact on hormone expression.
The findings show that many genes essential to hormone production are regulated by variations in methylation. “This study made it possible, for the first time, to describe in detail epigenetic profiles specific to each cell type. It shows that many genes essential for insulin and glucagon production are regulated by differences in DNA methylation,” explained lead author Charlotte Ling in a press release.
The researchers also identified marked alterations in diabetic patients. Among them, the epigenetic overexpression of the transcription factor ONECUT2 in beta cells appeared particularly significant. This abnormality disrupts cellular energy production and insulin secretion, potentially contributing to disease progression.
“Here, for the first time, we precisely show which regions regulate insulin and glucagon production through DNA methylation, giving us the opportunity to develop future epigenetics-based treatments,” emphasized Charlotte Ling. “This allows us to better understand why beta cells lose their function in diabetes. In the longer term, this knowledge could help us identify new personalized therapeutic targets,” she added.
What if damaged cells could be repaired?
This mapping represents a major advance in understanding the molecular mechanisms underlying type 2 diabetes. It highlights the dynamic role of the epigenome in both the function of pancreatic endocrine cells and their pathological alterations.
“We are now trying to understand which of these modifications are reversible and whether this could help beta cells recover their function in people with diabetes. A key issue is determining whether the effects of modifying DNA methylation persist in the cell over time,” explained Charlotte Ling.
Ultimately, this research opens the door to targeted therapeutic strategies capable of specifically modulating the epigenome. Such an approach could transform diabetes management by moving toward precision medicine based on cellular reprogramming.
Read next: Type 1 Diabetes: “Cyborg” transplants to restore the pancreas
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans.
Last press reviews
Hantavirus: how does the virus hijack the cell?
By Ana Espino | Published on May 11, 2026 | 4 min read<br><br><br><br>
Immune cells and systemic lupus: a global dysregulation of the immune system
By Ana Espino | Published on May 8, 2026 | 4 min read <br>